Cytomegalovirus in solid organ transplantation

Transplant Infectious Disease

Volumn 3, Issue SUPPL. 2, 2001, Pages 1-5

  Rubin, R H ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cytomegalovirus; Herpesvirus; Pathogenesis

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METICILLIN; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ALLOGRAFT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE COURSE; ECONOMIC EVALUATION; GRAFT REJECTION; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR DISEASE; VIRUS LOAD; VIRUS VIRULENCE; ANTIBIOTIC RESISTANCE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; DRUG USE; EDITORIAL; GRAFT VERSUS HOST REACTION; INFECTION; NEPHROTOXICITY; SURGICAL DRAINAGE; TRANSPLANTATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; IMMUNOGLOBULINS; ORGAN TRANSPLANTATION; ANTI-BACTERIAL AGENTS; INFECTION CONTROL; TRANSPLANTATION;

EID: 0035690715     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2001.003001001.x     Document Type: Review

References (33)

1. Post-transplant lymphoproliferative disorder
2. Pretransplantation assessment of the risk of lymphoproliferative disorder
3. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection
4. Anti-B cell and anti-cytokine therapy for the treatment of PTLD: Past, present, and future
5. Uninfected and cytomegalic endothelial sells in blood during cytomegalovirus infection: Effect of acute rejection
6. Direct detection of cytomegalovirus in peripheral blood leukocytes-a review of the antigenemia assay and polymerase chain reaction
7. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation
8. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection
9. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
10. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells
11. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNF-alpha is mediated via induction of NFκB
12. Infection in organ-transplant recipients
13. Mechanisms of human cytomegalovirus (HCMV) (re) activation and its impact on organ transplant patients
14. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients
15. Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure
16. High incidence of active cytomegalovirus infection among septic patients
17. Cytomegalovirus infection in patients with bacterial sepsis
18. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
19. Infection in the organ transplant recipient
20. The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: The case for passive-active immunization
21. 9-(1-3-dihidroxy-2-propoxymethyl) guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice
22. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
23. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: Interim comparison of a randomized and an open-label trial
24. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: Comparison of the randomized and open-label trials
25. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis
26. An unusual complication of cardiac transplantation-infected aortic pseudoaneurysm
27. Use of CMV-IGIV and ganciclovir for the prevention of CMV disease in lung transplantation
28. Role of CMV in cardiac allograft vasculopathy
29. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
30. Prevention of primary cytomegalovirus infection with oral ganciclovir prophylaxis
31. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
32. Human herpesvirus 6
33. Human herpesvirus 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus